Physician profile
Jin S Lim
NPI 1386641678
$1,762.66
in general payments reported to CMS, 2019-2025
16 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $42.36 · 2021: $68.55 · 2022: $163 · 2023: $407 · 2024: $258 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $519.13 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $316.78 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $297.45 | 2021-2025 | Nucala |
| Aerin Medical INC. | $251.99 | 2019-2023 | |
| Inspire Medical Systems, INC. | $76.80 | 2024-2025 | Inspire |
| Smith+Nephew, INC. | $42.44 | 2019 | |
| Stryker Corporation | $41.75 | 2019 | |
| Amgen INC. | $32.48 | 2025 | Tezspire |
| Acclarent, INC | $29.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.02 | 2025 | Tezspire |
| Neurent Medical Limited | $28.25 | 2023 | Neuromark Device, Neuromark Radiofrequency Console |
| Intersect Ent, INC. | $22.98 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.60 | 2025 | Elaprase |
| Ambu INC. | $20.30 | 2023 | |
| Optinose US, INC. | $19.00 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $13.23 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.